ArticleEuropean clinical respiratory journal2025
Detecting respiratory impairment in newly diagnosed rheumatoid arthritis by MRC dyspnoea scale and microfibrillar-associated protein 4.
Article in European clinical respiratory journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To evaluate the Medical Research Council (MRC) dyspnoea scale and serum Microfibrillar-associated protein 4 (MFAP4) levels for the detection of respiratory impairment in newly diagnosed rheumatoid arthritis (RA). Methods: Patients underwent blood tests, pulmonary function tests (PFT) and dyspnoea assessment using the MRC scale. Respiratory impairment was defined as a diffusion capacity of the lungs for carbon monoxide (DLCO) <80% predicted or FEV1/FVC <70%. The primary outcomes were the MRC and MFAP4's sensitivity, specificity, and diagnostic odds ratio (DOR) with 95% confidence intervals (CI). Results: One hundred and thirty-one patients had available baseline tests. Mean age was 57.7 years (SD: 10.9), 61% were female, and 45% had respiratory impairment. For MRC score ≥ 2, the sensitivity was 39.0% (95% CI 26.5; 52.6), specificity 76.4% (95% CI 64.9; 85.6), and DOR 2.07 (95% CI 0.97; 4.40). For MFAP4 > 29.0 U/mL, the sensitivity was 62.7% (95% CI 49.1; 75.0), specificity 56.9% (95% CI 44.7; 68.6), and DOR 2.22 (95% CI 1.10; 4.50). The DOR was 3.01 (95% CI 1.27; 7.16) for MFAP4 detecting respiratory impairment when adjusted for age, sex and smoking status. Conclusion: The MRC dyspnoea score and unadjusted MFAP4 levels were poor predictors of respiratory impairment in patients with early treatment-naïve rheumatoid arthritis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.